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Background: DRα1-mouse(m)MOG-35-55, a novel construct developed in our laboratory as a simpler and
potentially less immunogenic alternative to two-domain class II constructs, was shown previously to target the
MIF/CD74 pathway and to reverse clinical and histological signs of experimental autoimmune encephalomyelitis
(EAE) in DR*1501-Tg mice in a manner similar to the parent DR2β1-containing construct.
Methods: In order to determine whether DRα1-mMOG-35-55 could treat EAE in major histocompatibility complex
(MHC)-mismatched mice and to evaluate the treatment effect on central nervous system (CNS) inflammation,
C57BL/6 mice were treated with DRα1-mMOG-35-55. In addition, gene expression profile was analyzed in spinal
cords of EAE DR*1501-Tg mice that were treated with DRα1-mMOG-35-55.
Results: We here demonstrate that DRα1-mMOG-35-55 could effectively treat EAE in MHC-mismatched C57BL/6
mice by reducing CNS inflammation, potentially mediated in part through an increased frequency of M2 monocytes in
the spinal cord. Microarray analysis of spinal cord tissue from DRα1-mMOG-35-55-treated vs. vehicle control mice with
EAE revealed decreased expression of a large number of pro-inflammatory genes including CD74, NLRP3, and IL-1β
and increased expression of genes involved in myelin repair (MBP) and neuroregeneration (HUWE1).
Conclusion: These findings indicate that the DRα1-mMOG-35-55 construct retains therapeutic, anti-inflammatory, and
neuroprotective activities during treatment of EAE across MHC disparate barriers.
Keywords: Experimental autoimmune encephalomyelitis (EAE), Multiple sclerosis (MS), DRα1-mMOG-35-55 therapy, M2
macrophages, NeuroprotectionBackground
Multiple sclerosis (MS) is a complex neurological disease
with an autoimmune origin involving both genetic and
environmental factors in disease pathogenesis [1, 2]. The
major genetic effect has been attributed to the major
histocompatibility complex (MHC) region on chromosome* Correspondence: vandenba@ohsu.edu
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creativecommons.org/publicdomain/zero/1.0/6. Within this region, the highly polymorphic human
leukocyte antigen (HLA) class II genes, such as HLA-
DRB1 and HLA-DQB1, were associated with disease sus-
ceptibility [3–6]. Furthermore, several of the MHC genes
which are not polymorphic were shown to be involved in
disease progression, including the class II invariant chain
(CD74) [7].
We previously demonstrated enhanced CD74 cell surface
expression on monocytes in mice with experimental auto-
immune encephalomyelitis (EAE) [7]. In addition to stabil-
izing and chaperoning MHC class II molecules to the cellarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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macrophage migration inhibitory factor (MIF), a pleiotropic
pro-inflammatory protein involved in many inflammatory
and autoimmune diseases [8–16]. MIF engagement of
CD74 leads to the recruitment and activation of CD44 and
CXCR2/4 to initiate signaling pathways necessary for
MAPK activation, which leads to cell motility and increased
survival [17–19]. Mif−/− (MIF-KO) mice exhibit only acute
EAE signs but no further progression of clinical disease,
correlating with the role of central nervous system (CNS)-
infiltrating monocytes in disease progression [20, 13].
Macrophages and microglia play a central role in multiple
sclerosis and EAE, which is affected by the polarization
state of these cells [21–23]. Classically activated macro-
phages (M1) govern the CNS during the early stages of
these diseases, secreting pro-inflammatory cytokines
and activating effector T cells. During the later phase of
disease, alternatively activated macrophages (M2) re-
lease anti-inflammatory cytokines and promote tissue
repair [22, 24–28].
We recently demonstrated a previously unrecognized
immunoregulatory interaction in which the HLA-DRα1
polypeptide can inhibit MIF binding to mouse CD74
and downstream signaling, resulting in rapid and potent
treatment of ongoing clinical and histological signs of
EAE in HLA-DR2-Tg mice [29]. The binding of the
DRα1 construct to both human and mouse CD74 and
its subsequent blocking of MIF interaction and signaling
thus might represent a natural immunoregulatory role
for the DRα1 domain in terminating/regulating MIF-
dependent inflammation. In addition, we demonstrated
that the potency of the DRα1 domain could be enhanced
by addition of a peptide extension (MOG-35-55 peptide)
that provided secondary structure not present in DRα1
[29]. The invariable DRα1 domain is present in all hu-
man subjects and should not be recognized as immuno-
logically foreign. In order to assess whether effective
treatment with DRα1 constructs could occur under
histoincompatible conditions and thus obviate any need
to carry out HLA screening prior to injection, we treated
EAE in C57BL/6 mice with DRα1-mMOG-35-55
(a complete MHC mismatch) and evaluated disease pro-
gression and CNS inflammation.
Herein, we demonstrate that DRα1-mMOG-35-55 re-
verses EAE clinical signs in C57BL/6 mice, inhibitsFig. 1 Schematic illustration of the DRα1-mMOG-35-55 constructinfiltration of activated monocytes and CD4+ T cells into
the CNS, and increases the frequency of CD11b+ CD206+
(M2) monocytes in the spinal cord. Furthermore, micro-
array analysis of spinal cords of DRα1-mMOG-35-55-
treated DR*1501-Tg mice with EAE revealed that the
expression of pro-inflammatory genes was dramatically
reduced after DRα1-mMOG-35-55 treatment relative
to vehicle treatment, while the expression of myelin
basic protein (MBP) and other genes that were shown




C57BL/6 mice were purchased from Jackson laboratory.
DR*1501-Tg and DR*1502-Tg mice were bred in-house
at the Veterinary Medical Unit, VA Portland Health Care
System, and used at 8–12 weeks of age. All procedures
were approved and performed according to federal, state,
and institutional guidelines.
DRα1-mMOG-35-55 cloning, production, and purification
Cloning, production, and purification of the DRα1-
mMOG-35-55 construct have been described previously
[29]. Briefly, DRα1-mMOG-35-55 was built as a single
gene joining the mouse (m)MOG-35-55-encoding DNA
sequence upstream of the HLA-DRα1 domain with a
flexible linker (containing a thrombin cleavage site) be-
tween both elements as shown in Fig. 1. This single gene
was cloned between the NcoI and XhoI restriction sites
of the pET21d(+) vector, expressed in Escherichia coli,
and the protein purified following standard purification
techniques including anion exchange and size exclusion
chromatography in the presence of 6 M urea. Protein
was refolded after extensive dialysis in 20 mM Tris, pH
8.5; concentrated; and flash frozen.
Induction of EAE
DR*1501-Tg and DR*1502-Tg mice were screened for
the expression of the HLA marker by flow cytometry
[30]. Mice between 8 and 12 weeks of age were immu-
nized s.c. at four sites on the flanks with 0.2 ml of an
emulsion of 200 μg immunogenic peptide and complete
Freund’s adjuvant containing 400 μg of heat-killed Myco-
bacterium tuberculosis H37RA [30] (Difco, Detroit, MI).
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List Biological Laboratories (Campbell, CA) on days 0
and 2 post-immunization (75 and 200 ng per mouse, re-
spectively). Immunized mice were assessed daily for clin-
ical signs of EAE on a 6-point scale of combined hind
limb and forelimb paralysis scores. The following were
used for hind limb scores: 0 = no signs; 0.5 = limp tail
or mild hind limb weakness (i.e., a mouse cannot resist
inversion after a 90° turn of the base of the tail); 1 = limp
tail and mild hind limb weakness; 2 = limp tail and moder-
ate hind limb weakness (i.e., an inability of the mouse to
rapidly right itself after inversion); 3 = limp tail and mod-
erately severe hind limb weakness (i.e., inability of the
mouse to right itself after inversion and clear tilting of
hind quarters to either side while walking); 4 = limp tail
and severe hind limb weakness (hind feet can move but
drag more frequently than face forward); and 5 = limp tail
and paraplegia (no movement of hind limbs). Front limb
paralysis scores are either 0.5 for clear restriction in nor-
mal movement or 1 for complete forelimb paralysis. The
combined score is the sum of the hind limb score and the
forelimb score. Rarely, there is mortality of mice with se-
vere EAE, and in these cases, mice are scored as a 6 for
the remainder of the experiment. Mean EAE scores and
standard deviations for mice grouped according to initi-
ation of DRα1-mMOG-35-55 or vehicle treatment were
calculated for each day and summed for the entire experi-
ment (cumulative disease index (CDI) represents total dis-
ease load).
DRα1-mMOG-35-55 treatment of EAE
One hundred micrograms of DRα1-mMOG-35-55 pro-
tein was injected s.c. daily for 3 or 5 days to treat EAE
induced in C57BL/6, DR*1501-Tg, and DR*1502-Tg
mice, and clinical signs were scored as described above.
LPS and MIF in vitro stimulation
Cells were stimulated with 10 ng/ml of lipopolysacchar-
ide (LPS) (E. coli 0111:B4) with or without 100 ng/ml re-
combinant human MIF [31].
Flow cytometry
Four-color (fluorescein isothiocyanate (FITC), phyco-
erythrin, (PE), propidium iodide (PI), and allophycocya-
nin, (APC)) fluorescence flow cytometry analyses were
performed to determine the phenotypes of cells following
standard antibody staining procedures. For splenocytes,
single-cell suspensions of spleens from vehicle- and
DRα1-mMOG-35-55-treated groups were prepared by
homogenizing the tissue through a fine mesh screen.
Cells were pelleted after lysis of red cells followed by
washing twice with RPMI. Mononuclear cells from the
spinal cord or brain were isolated by Percoll gradient
centrifugation as previously described [32]. Cells fromthe spleen, spinal cord, or brain were resuspended in
staining medium (5 % BSA, 1× PBS, and 0.02 % sodium
azide) for FACS staining. For intracellular staining, cells
were resuspended (2 × 106 cells/ml) in stimulation media
(RPMI 1640 media containing 2 % FCS, 1 mM pyruvate,
200 μg/ml penicillin, 200 U/ml streptomycin, 4 mM L-
glutamine, and 5 × 10−5 M 2-β-ME with phorbol 12-
myristate 13-acetate (PMA) [50 ng/ml], ionomycin [500
ng/ml], and Brefeldin A [10 μg/ml] [all reagents from BD
Biosciences]) for 4 h. Fc receptors were blocked with
mouse Fc receptor-specific mAb (2.3G2; BD Pharmingen)
before cell surface staining and then fixed and perme-
abilized using a Cytofix/Cytoperm kit (BD Biosciences) ac-
cording to the manufacturer’s instructions. Permeabilized
cells were washed with Permeabilization Buffer (BD Bio-
sciences) and stained with either PE-conjugated IFN-γ,
APC-conjugated IL-17, or isotype-matched mAb that
served as a negative control. Data were collected with
CELLQUEST (BD Biosciences, San Jose, CA) and FCS
Express (De Novo Software, Los Angeles, CA) software
on a FACSCalibur (BD Biosciences) or with Accuri C6
(BD Biosciences).
After staining, cells were washed with staining medium
and analyzed immediately with a FACSCalibur using FCS
Express (Los Angeles, CA) software or with Accuri C6
(BD Biosciences). Absolute numbers of cells were calcu-
lated from live-gated cells. All antibodies were purchased
from BD Pharmingen (San Diego, CA), eBioscience (San
Diego, CA), or Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA) unless otherwise indicated.
Microarray analysis
Labeled target cDNA was prepared from spinal cord
total RNA samples that were pooled from three vehicle-
treated or three DRα1-mMOG-35-55-treated DR*1501-Tg
mice with EAE. Samples were amplified and labeled ac-
cording to the Affymetrix GeneChip WT Plus protocol.
Amplified and labeled cDNA target samples were each
hybridized to Mouse Gene 2.0 ST array. Image process-
ing was performed using Affymetrix Command Console
(AGCC) v.3.1.1 software, and expression analysis was
performed using Affymetrix Expression Console v.1.1
software.
Accession code
The accession code is Geo: microarray data GSE68805.
Functional annotation of expression modules
Gene ontology (GO) category enrichment analysis was
performed using WebGestalt software [33, 34]. Briefly,
GO enrichment is calculated by comparing the frequency
of genes from each different GO present in the set of dif-
ferently expressed genes to the frequency of genes for the
same GO in the mouse genome background.
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Whole spinal cords or mononuclear cells that were iso-
lated from spinal cords were isolated from DR*1501-Tg
mice. Total RNA was isolated from cells using an RNeasy
cultured cell kit according to the manufacturer’s instruc-
tions (Qiagen, Valencia, CA, USA). Quantitative real-time
PCR was performed using the StepOne Plus system with
gene-on-demand assay products (Applied Biosystems) for
TaqMan array mouse immune response or for CD74
(Assay ID: Mm00658576_m1), IL-1b (Assay ID: Mm004
24228_m1), NLRP3 (Assay ID: Mm00840904_m1), HDA
C5 (Assay ID: Mm0124076_m1), HUWE1 (Assay ID: Mm
00615533_m1), and MBP (Assay ID: Mm01266402_m1).
GAPDH housekeeping gene was amplified as an endogen-
ous control. Primers were used according to the manufac-
turer’s instructions.Statistical analysis
Daily mean scores were statistically analyzed by a two-
tailed Mann–Whitney U test for a nonparametric com-
parison between vehicle and DRα1-mMOG-35-55 treat-
ment groups. Mean CDIs were analyzed by Student’s t
test. Values of p < 0.05 were considered significant.Results
DRα1-mMOG-35-55 treatment reverses clinical signs of EAE
We demonstrated recently that DRα1-mMOG-35-55
treatment could reverse clinical signs of EAE in DR*1501-
Tg mice [29]. In order to test if the DRα1-mMOG-35-55
construct could treat EAE in mice that express the I-A/I-E
genes, as opposed to the human HLA-DRα1 and DR2β1
domains in the DR*1501-Tg mice, C57BL/6 mice were im-
munized with mouse (m)MOG-35-55/CFA/Ptx. Treat-
ment with DRα1-mMOG-35-55 (100 μg daily × 5) after
disease onset at a clinical score of 2 significantly reducedFig. 2 DRα1-mMOG-35-55 treats clinical EAE. C57BL/6 male WT mice with
score of 2 with vehicle or DRα1-mMOG-35-55 (100 μg daily × 5, black arrow
index scores (right) are shown. **p < 0.01, ***p < 0.001. Daily mean scoresclinical EAE scores compared with vehicle-treated mice
(Fig. 2).
We further evaluated DRα1-mMOG-35-55 treatment
efficacy vs. EAE induced in DR*1502-Tg mice that had
minor disparities in both MHC (I-Eαk:DR2*1502β chains)
and encephalitogenic peptide (hMOG-35-55 peptide con-
taining the S42P substitution). As observed for the
C57BL/6 mice, treatment with DRα1-mMOG-35-55 (100
μg daily × 5) after disease onset at a clinical score of 2
significantly reduced clinical EAE scores compared with
vehicle-treated mice (Additional file 1: Figure S1).
These results indicate that DRα1-mMOG-35-55 is a
potent therapeutic agent to treat EAE in mouse strains
expressing different MHC genes induced with a differ-
ent peptide than that contained within the DRα1-
mMOG-35-55 construct.DRα1-mMOG-35-55 treatment increases splenocyte
number but does not alter their activation state
To evaluate the effects of the DRα1-mMOG-35-55 con-
struct on inflammatory cells in the periphery, spleen
cells were isolated and analyzed on day 5 post-treatment
(24 h after the last treatment). As shown in Fig. 3a, b,
the absolute number of spleen cells was significantly in-
creased in DRα1-mMOG-35-55-treated mice compared
with vehicle-treated mice (148.5 × 106 ± 37.9 vs. 64.7 ×
106 ± 19.0, respectively, p < 0.001) as were the absolute
numbers of CD4+, CD19+, CD11b+, and CD11c+ spleen
cell subtypes. However, analysis of expression of activation
markers (CD44 and CD69) on CD4+ T cells revealed no
significant differences in splenocytes from mice with
EAE after DRα1-mMOG-35-55 vs. vehicle treatment.
In addition, there was no difference in the intracellular
expression of IFN-γ or IL-17 after PMA/ionomycin
stimulation of spleen cells from mice that were treated
with DRα1-mMOG-35-55 vs. vehicle (Fig. 3c, d).mMOG-35-55-induced EAE were treated after disease onset at a clinical
s). Mean clinical EAE daily disease scores (left) and cumulative disease
were analyzed by Mann–Whitney U and mean CDI by Student’s t test
Fig. 3 DRα1-mMOG-35-55 treatment increases splenocyte number but does not affect their activation state. a Representative image of spleens of
vehicle-treated (n = 8) or DRα1-mMOG-35-55-treated (n = 8) C57BL/6 male WT mice with EAE. b Absolute cell numbers of CD4+, CD19+, CD11b+,
and CD11c+ cells in spleen. c Frequency of CD4+CD69+ and CD4+CD44+ (activated CD4+ T cells) in spleen. d Splenocytes from DRα1-mMOG-35-
55-treated (n = 4) and vehicle-treated (n = 4) mice were stimulated with PMA (50 ng/ml) and ionomycin (500 ng/ml) for 4 h. CD4+ T cells were
evaluated for the intracellular expression of IFN-γ or IL-17 by flow cytometry. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p <
0.001, Student’s t test
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CNS-infiltrating cells and their activation state
We reported previously that two-domain partial MHC
class II constructs could reduce EAE severity and CNS
inflammation by reducing the number and frequency of
activated cells in DR*1501-Tg mice. In order to evaluate
if DRα1-mMOG-35-55 treatment of C57BL/6 mice had
a similar effect, mononuclear cells were isolated from
brains and spinal cords from DRα1-mMOG-35-55- or
vehicle-treated mice 5 days post-EAE treatment. The ab-
solute number of mononuclear cells was reduced both
in the brain (8.25 × 104 ± 1.2 vs. 18.75 × 104 ± 3.2, p <
0.001) and spinal cord (0.64 × 106 ± 0.4 vs. 1.76 × 106 ±
1.15, p < 0.01), respectively, of DRα1-mMOG-35-55-
treated vs. vehicle-treated mice with EAE (Fig. 4a). This
reduction was reflected in the absolute number of infil-
trating monocytes and activated resident microglia
(CD11b+CD45hi) as well as CD3+ T cells in the spinal
cord (p < 0.05, Fig. 4b). In addition, the CD74 expression
level on CD11b+CD45hi cells was significantly lower in
the spinal cords of DRα1-mMOG-35-55- vs. vehicle-
treated mice (p < 0.05, Fig. 4c), in accordance witheffects of the parent DR*1501 β1α1-mMOG-35-55 con-
struct in DR*1501-Tg mice [30]. Furthermore, there was
a significantly lower frequency of PMA/ionomycin-stim-
ulated IL-17+ T cells but not CD4+ IFN-γ+ Τ cells from
DRα1-mMOG-35-55-treated mice compared with stim-
ulated cells from vehicle-treated mice (p < 0.05, Fig. 4d).
Taken together, these data suggest that DRα1-mMOG-
35-55 inhibits migration of activated inflammatory cells
from the periphery to the CNS of C57BL/6 mice and
that the infiltrating cells in the spinal cords of DRα1-
mMOG-35-55-treated mice have reduced expression of
CD74 and are less inflammatory compared with spinal
cord cells from vehicle-treated mice.
DRα1-mMOG-35-55 treatment enhances the frequency of
CD11b+CD206+ M2 macrophages in spinal cords of mice
with EAE
During EAE, M1 macrophages were shown to induce
CNS inflammation, whereas M2 macrophages were
shown to be involved in neuroprotection and remyelina-
tion [22, 24, 23]. We analyzed the frequency of activated
CD11b+CD206+ M2 macrophages in spinal cords of
Fig. 4 DRα1-mMOG-35-55 treatment reduces the number and activation state of CNS-infiltrating cells. a Absolute lymphocyte numbers in the
spinal cord (n = 8) and brain (n = 4) from DRα1-MOG-35-55- or vehicle-treated C57BL/6 male WT mice with EAE. b Absolute numbers of
CD11b+CD45high and CD3+ T cells in spinal cords. c CD74 cell surface expression on CD11b+CD45high cells in spinal cords. d Brain lymphocytes
from DRα1-mMOG-35-55-treated (n = 4) and vehicle-treated (n = 4) mice were stimulated with PMA (50 ng/ml) and ionomycin (500 ng/ml) for 4 h.
CD4+ T cells were evaluated for the intracellular expression of IFN-γ or IL-17 by flow cytometry. Data are presented as mean ± SD. *p < 0.05, **p < 0.01,
***p < 0.001, Student’s t test
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with DRα1-mMOG-35-55 or vehicle. As shown in Fig. 5a,
the frequency of M2 macrophages (CD11b+CD206+) was
significantly increased in DRα1-mMOG-35-55-treated vs.
vehicle-treated mice (p < 0.05). In contrast, no difference
in CD11b+CD206+ frequency was observed in the periph-
ery (Fig. 5b).
In order to determine whether DRα1-mMOG-35-55
could directly induce M2 polarization, we isolated spleen
cells from untreated C57BL/6 mice with EAE on day 15
post-immunization and stimulated them with LPS, LPS/
MIF, LPS/MIF/DRα1-mMOG-35-55, or DRα1-mMOG-
35-55 alone for 24 h at 37 °C. As expected, LPS or LPS/
MIF treatment reduced the CD11b+CD206+ frequency
(p < 0.001). However, treatment with LPS, MIF and
DRα1-mMOG-35-55, or DRα1-mMOG-35-55 alone sig-
nificantly increased the frequency of CD11b+CD206+
cells compared to LPS or LPS + MIF treatment (p < 0.001),
but not to control levels (Fig. 5c).
We confirmed the increase in CD11b+CD206+ cells in
spinal cords from DR*1501-Tg mice that were immu-
nized with mMOG-35-55/CFA/Ptx and treated with
DRα1-mMOG-35-55 (p < 0.05, Additional file 1: FigureS2a). Moreover, in vitro stimulation of spleen cells from
naïve DR*1501-Tg mice showed similar results of an in-
creased frequency of CD11b+CD206+ cells after DRα1-
mMOG-35-55 treatment compared to LPS or LPS/MIF
(p < 0.05, Additional file 1: Figure S2b), but not greater
than controls. Thus, we conclude that DRα1-mMOG-
35-55 treatment inhibits the pro-inflammatory effect of
M1 polarization conditions but apparently does not dir-
ectly induce M2 polarization.
DRα1-mMOG-35-55 treatment of EAE reduces the
expression of pro-inflammatory genes and increases the
expression of genes involved in neurosurvival and
regeneration
To evaluate DRα1-mMOG-35-55 effects on CNS inflam-
mation during EAE in a more comprehensive manner,
we performed microarray analysis on spinal cords from
DRα1-mMOG-35-55- vs. vehicle-treated DR*1501-Tg
mice with EAE. EAE was induced with mMOG-35-55/
CFA/Ptx, and mice were treated with DRα1-mMOG-35-55
(100 μg daily × 3) or vehicle after disease onset at a clinical
score of 2. Twenty-four hours after the last treatment, total
RNA was isolated from spinal cords and gene expression
Fig. 5 DRα1-mMOG-35-55 treatment increases the frequency of CD11b+CD206+ M2 macrophages in spinal cords of mice with EAE. a Frequency
of CD206+ on CD11b+CD45hi cells from spinal cords of DRα1-mMOG-35-55-treated (n = 6) vs. vehicle-treated (n = 6) C57BL/6 male WT mice with
EAE. b Frequency of CD206+ on CD11b+CD45hi cells from spleens of DRα1-mMOG-35-55-treated (n = 6) or vehicle-treated (n = 6) C57BL/6 male
WT mice with EAE. c Splenocytes from C57BL/6 male WT mice (n = 4) with EAE (day 15 post-immunization) were treated with 10 ng/ml LPS, 100
ng/ml recombinant MIF, and 25 μg/ml DRα1-mMOG-35-55 for 24 h. Frequency of CD206+ on CD11b+F4/80+ cells was evaluated by flow cytometry.
Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. a, b Student’s t test. c One-way ANOVA with Tukey post-test
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Gene 2.0 ST Affymetrix GeneChip system (Geo: micro-
array data GSE68805 and Additional file 2: Table S1).
As shown in Fig. 6a, relative up- or downregulated
genes after treatment with DRα1-mMOG-35-55 plotted
against their expression level in spinal cords of vehicle-
treated mice revealed 1049 probes that were downregu-
lated by twofold or greater. Out of these probes, 160
genes were shown to be involved in inflammation pro-
cesses. Conversely, 568 probes were upregulated by
twofold or greater in the spinal cord of DRα1-mMOG-
35-55-treated vs. vehicle-treated mice. Gene ontology
analysis of the genes that were upregulated did not in-
dicate a distinct pathway that was enriched as was ob-
served for downregulated pro-inflammatory response
genes. However, several of the genes that were relatively
upregulated by DRα1-mMOG-35-55 treatment wereshown to be involved in neuroregeneration, including
Prosaposin (PSAP), Myocilin (MYOC), E3 ubiquitin ligase
Huwe1, and 3-phosphoinositide-dependent protein kinase
1 (PDPK-1) [35–40]. We validated these microarray re-
sults by real-time PCR analysis of spinal cord mRNA
from three individual mice in each group. Indeed, pro-
inflammatory genes such as CD74, Nlrp3, and IL-1b
were significantly downregulated in spinal cords of
DRα1-mMOG-35-55-treated vs. vehicle-treated mice
(p < 0.001, p < 0.01, and p < 0.001, respectively),
whereas Huwe1 and MBP were significantly upregulated
(p < 0.05). Histone deacetylase 5 (HDAC5) was also up-
regulated, although results did not reach significance
(Fig. 6b) [41, 42]. These results indicate the CNS of DRα1-
mMOG-35-55-treated mice is not only less inflammatory
but also that this treatment could inhibit and potentially
reverse ongoing demyelination and neurodegeneration.
Fig. 6 DRα1-mMOG-35-55 treatment reduces the expression of pro-inflammatory genes and increases the expression of genes involved in neurosurvival
and regeneration. a Gene expression profile of spinal cords of DR*1501-Tg mice with EAE that were treated with DRα1-mMOG-35-55 (n = 3) or vehicle
(n = 3). mRNA was pooled for microarray analysis. Gray circles represent probes that were at least twofold down- or upregulated after DRα1-mMOG-35-55
treatment relative to vehicle treatment. b Relative expression of mRNA of CD74, NLRP3, IL-1b, HUWE1, MBP, and HDAC5 was analyzed by real-time PCR
from spinal cord samples of DRα1-MOG-35-55-treated (n = 3) relative to vehicle-treated (n = 3) mice. *p < 0.05, **p < 0.01, p < 0.001, Student’s t test
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Two-domain α1β1/peptide partial MHC class II con-
structs were shown to be highly beneficial in treating
EAE, a widely utilized animal model for MS [43, 30].
One such single-exon construct, RTL1000, containing
the human MOG-35-55 peptide linked to the DR2β1
and DRα1 domains through a flexible linker was recently
tested successfully in a phase 1 clinical trial in HLA-DR2+
MS subjects [44]. However, treatment with RTL1000
would currently require HLA screening of ~50 % of MS
patients who are DR2+, with the remaining 50 % of
HLA-mismatched subjects not eligible to enroll in
RTL1000 trials. A major goal of this study was to deter-
mine if the DRα1-mMOG-35-55 construct could effect-
ively treat EAE in C57BL/6 mice, in which the DRα1
domain represents a mismatch with the mouse H-2
MHC molecules. The results of this study clearly dem-
onstrate that DRα1-mMOG-35-55 treatment of EAE in
C57BL/6 mice produced a highly significant reduction
of CNS inflammation, mainly by inhibiting the infiltration
of pro-inflammatory cells from the periphery. We recently
demonstrated that the DRα1-mMOG-35-55 construct
could treat experimental stroke in DR*1502-Tg mice. Four
daily treatments with DRα1-mMOG-35-55 reduced in-
farct size by 40 % in the cortex, striatum, and hemisphere;
inhibited the migration of activated CD11b+CD45high cells
from the periphery to the brain; and reversed splenic atro-
phy [45]. In the current study, we also show that DRα1-mMOG-35-55 can effectively treat DR*1502-Tg mice with
EAE induced by human MOG-35-55 peptide, a different
model with minor MHC and peptide mismatches with the
DRα1-mMOG-35-55 construct. DRB1*1502 is nearly iden-
tical to DRB1*1501 in primary amino acid sequence except
for a glycine for valine substitution at position 86 that con-
tributes to the P1 pocket involved in peptide binding. The
smaller glycine residue at position 86 of the DRB1*1502
molecule likely enlarges the P1 pocket to permit binding of
large hydrophobic residues such as tyrosine or tryptophan
such as that found in m or hMOG-35-55, which are not
bound as easily by the P1 pocket in the DRB1*1501 allele.
In the DR*1502-Tg mice, the DRB1*1502 transgene
pairs with the mouse I-Eαk chain to form a functional
MHC complex on the cell surface [46]. I-A is not
expressed in these mice because they were derived from
Ab0 mouse class II knockout mice [47]. Responses to
antigen in these mice are thus restricted mainly by human
DR2, and to that extent, they are able to pair in mice
expressing the DRB1*1502 transgene, possibly by mouse
class II I-Eαk/I-Eβb.
In addition, we previously found that DRα1-mMOG-
35-55 could attenuate MBP-induced EAE [29]. Hence,
this novel construct could treat different CNS diseases
in different mouse strains that are mismatched in the
DRα1 domain or diseases that were induced by a different
myelin peptide than mMOG-35-55 that is covalently
linked to the DRα1 domain. Although not fully addressed
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blockade by antagonist interactions between DRα1-
mMOG-35-55 and mouse CD74 consistent with our
previous observations in DR*1501-Tg mice derived on
the C57BL/6 background.
Previously, we showed that the DRα1 domain binds to
CD74 on the monocyte cell surface and downregulates
CD74 expression and blocks MIF binding and signaling
[48, 7]. This blockade of MIF signaling affects cell migra-
tion into the CNS during EAE, thus resulting in a less
inflammatory milieu. Indeed, treatment with the DRα1-
mMOG-35-55 construct reduced expression of CD74,
resulting in a significant decrease in the absolute num-
ber of activated CD11b+ macrophages/monocytes and T
cells in the CNS of C57BL/6 mice. It is important to
note that this effect was due not only to blocking the
entry of infiltrating cells into the CNS but also to previ-
ously infiltrated cells since mice were treated with DRα1-
mMOG-35-55 at the onset of marked clinical signs, well
after the entry of infiltrating cells into the CNS.
Our data indicate that the DRα1-mMOG-35-55 con-
struct, which contains the human HLA-DRα1 domain,
could effectively bind to the mouse CD74 molecule. This
might be due to its high level of similarity (~75%) with
the human CD74 molecule. We are currently trying to
identify the exact binding region of the DRα1 on CD74.
Furthermore, although we previously showed that CD11b+
monocytes are the predominant cell population that is
binding the DRα1 constructs, it is clear that in vivo treat-
ment affects other cell types as well. We demonstrated that
CD4+ T cells in the CNS of DRα1-mMOG-35-55-treated
mice express lower levels of IL-17 compared with vehicle-
treated mice. Whether this effect could be direct or indirect
is the subject of a current investigation.
Macrophages have a central role in MS pathology
[20, 26, 22, 49]. They are involved in different stages of
the disease and assume a diversity of distinct activation
states. Although the range of activation of macro-
phages is very wide, it is acceptable to characterize at
least two opposing activation states: The classically ac-
tivated macrophages (M1) express high levels of CD86,
CD80, and MHC class II on their cell surface and are
very potent in priming T cells and recruiting them to
the CNS. These cells are predominantly present in the
early stages of EAE. One the other side of the activa-
tion spectrum, alternatively activated macrophages
(M2) express high levels of CD206, CD163, and argi-
nase1 and low levels of CD40, CD86, and MHC class II
[21]. Several studies suggested that M2 macrophages
have a beneficial function in EAE, both in inhibiting in-
flammation and in inducing remyelination by phago-
cytosis of myelin debris [24, 25, 28]. In our present
work, we found an increased frequency of CD206+
CD11b+CD45hi cells in the spinal cords of DRα1-mMOG-35-55- vs. vehicle-treated mice with EAE. This
was observed both in C57BL/6 and in DR*1501-Tg
mice. This observation is in line with the low expres-
sion levels of CD74 on these activated cells from
treated mice. Interestingly, there was no difference in
the frequency of CD206+ monocytes in the periphery.
Furthermore, in vitro analysis of activated cells showed
that while LPS or LPS and MIF stimulation decreased
the frequency of CD206+CD11b+ cells, DRα1-mMOG-
35-55 treatment partially reversed the LPS effect. How-
ever, treatment with DRα1-mMOG-35-55 alone did
not induce a higher frequency of CD11b+CD206+ cells
above the control level, suggesting that DRα1-mMOG-
35-55 has an inhibitory effect on pro-inflammatory
stimuli rather than a direct stimulatory effect on M2
cells. It was reported previously that MIF-KO mice
have a higher frequency of M2 cells compared with
WT mice [50]. In addition, since we previously demon-
strated that DRα1 blocks MIF binding, spleen cells
were stimulated in vitro with LPS or LPS and MIF in
order to evaluate that effect of MIF on M2 reduction
and the role of DRα1-mMOG-35-55 in blocking MIF
signaling. However, we did not detect an additive effect
of the MIF over the LPS. It is possible that effects of
added exogenous MIF are not detectable since LPS
stimulation is inducing sufficient endogenous MIF. It
would be of interest in future studies to assess the M1/
M2 ratio in the CNS of MIF-deficient mice with EAE.
Analysis of a gene expression profile of spinal cords
from DRα1-mMOG-35-55-treated mice relative to
vehicle-treated mice demonstrated a wide reduction in
the expression of pro-inflammatory genes. This effect
might be due to the combination of a low number of ac-
tivated cells in the spinal cord of DRα1-mMOG-35-55-
treated mice and to the DRα1-mMOG-35-55 effect on
the activation levels of the inflammatory cells that are in
the CNS.
We also demonstrated for the first time that the
DRα1-mMOG-35-55 construct could increase the ex-
pression of genes that are involved in myelin repair and
neural survival or regeneration relative to vehicle. In
addition to MBP expression that was elevated in the
DRα1-mMOG-35-55-treated group, we observed in-
creased expression of genes such as HUWE1, PROSA-
POSIN, and MYOCILIN. The ubiquitin ligase HUWE1
was shown to regulate glia differentiation and to have an
essential role in the proliferation and differentiation of
neural progenitor cells [35, 39]. PROSAPOSIN is the
precursor protein for four lysosomal activator proteins
(saposins A–D), and it can also be secreted as a full-
length protein. It was shown that PROSAPOSIN could
protect myelinating glial cells, enhance nerve regener-
ation, and promote synaptic development [38]. It was re-
cently shown that MYOCILIN is involved in myelination
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the acute phase of EAE, the expression levels of these
genes are downregulated in the CNS compared with a
less inflammatory CNS. Interestingly, in a previous work,
it was shown that treatment of EAE with a partial MHC
class II construct could reduce demyelination, axonal
loss, and ongoing damage [51]. Those experiments also
suggested that such treatment could induce repair of
myelin and axonal damage. Additional experiments are
in progress to determine whether DRα1-mMOG-35-55
can directly induce repair of axonal damage during EAE.
Conclusion
In summary, our work indicates that the DRα1-mMOG-
35-55 construct could treat EAE in part by reducing
CNS inflammation. Because the DRα1 and the CD74
(MHC class II invariant chain) amino acid sequences are
conserved in humans, the recombinant DRα1-MOG-35-55
construct potentially represents an immunotherapy that
would not require HLA screening prior to use. In addition
to inhibition of pro-inflammatory factors, we show an in-
crease in the frequency of M2 macrophages in the spinal
cord of DRα1-mMOG-35-55-treated mice. Thus, our data
demonstrate that this treatment could inhibit additional
damage caused by inflammation and set the appropriate
conditions for repair of myelin and axonal damage.
Additional files
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